SCHEMBL8229629

SCHEMBL8229629

Cc1oc2ccc(N)cc2c1C

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK9 P50750 1/20 0.59
DYRK1A Q13627 1/20 0.59
DYRK2 Q92630 1/20 0.59
RAB9A P51151 5/20 0.53
NPC1 O15118 4/20 0.53
SMN1; SMN2 Q16637 4/20 0.53
MAPT P10636 4/20 0.53
GFER P55789 1/20 0.53
ALDH1A1 P00352 8/20 0.52
KDM4E B2RXH2 5/20 0.52
KMT2A Q03164 4/20 0.52
HPGD P15428 3/20 0.52
MEN1 O00255 2/20 0.52
MAPK1 P28482 1/20 0.46
ALDH2 P05091 5/20 0.46
ALDH1A2 O94788 4/20 0.46
ALDH1B1 P30837 4/20 0.46
ALDH1A3 P47895 3/20 0.46
EGFR P00533 1/20 0.43
SRC P12931 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11228880 0.85 SMN1; SMN2 (0.67) CDK9DYRK1ADYRK2RAB9ANPC1
SCHEMBL20364194 0.83 ALDH1A1 (0.55) CDK9DYRK1ADYRK2RAB9ANPC1
SCHEMBL172349 0.78 CDK9 (0.53) CDK9DYRK1ADYRK2RAB9ANPC1
SCHEMBL17456346 0.77 NPC1 (0.47) CDK9DYRK1ADYRK2RAB9ANPC1
SCHEMBL4760425 0.77 NPC1 (0.78) RAB9ANPC1SMN1; SMN2MAPTGFER
SCHEMBL30340803 0.77 NPC1 (0.78) RAB9ANPC1SMN1; SMN2MAPTGFER
SCHEMBL22298393 0.76 SMN1; SMN2 (0.46) CDK9DYRK1ADYRK2RAB9ANPC1
SCHEMBL3894812 0.75 CDK9 (0.50) CDK9DYRK1ADYRK2RAB9ANPC1
SCHEMBL14409919 0.75 MCL1 (0.59) CDK9DYRK1ADYRK2ALDH1A1KDM4E
SCHEMBL12301447 0.75 LMNA (0.51) CDK9DYRK1ADYRK2RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230174488-A1 SARS-COV-2 INHIBITORS HAVING COVALENT MODIFICATIONS FOR TREATING CORONAVIRUS INFECTIONS INSILICO MEDICINE IP LIMITED (HK) 2023-06-08 US disclosed
US-10640490-B2 Diaminopyrimidine derivatives and processes for the preparation thereof YUHAN CORPORATION (KR) 2020-05-05 US disclosed
US-20180072705-A1 DIAMINOPYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF YUHAN CORPORATION (KR) 2018-03-15 US disclosed
US-9850227-B2 Diaminopyrimidine derivatives and processes for the preparation thereof YUHAN CORPORATION (KR) 2017-12-26 US disclosed
EP-2678331-B1 DIAMINOPYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF YUHAN CORP (KR) 2016-04-27 EP disclosed
EP-2678331-A2 DIAMINOPYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF Yuhan Corporation (KR) 2014-01-01 EP disclosed
US-20130331377-A1 DIAMINOPYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF YUHAN CORPORATION (KR) 2013-12-12 US disclosed
WO-2012115479-A2 DIAMINOPYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF YUHAN CORPORATION (KR) 2012-08-30 WO disclosed
WO-2012115478-A2 DIAMINOPYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF YUHAN CORPORATION (KR) 2012-08-30 WO disclosed
WO-2007139856-A2 HETEROBICYCLIC METALLOPROTEASE INHIBITORS ALANTOS PHARMACEUTICALS, INC. (US) 2007-12-06 WO disclosed
WO-2006128184-A2 PYRIMIDINE OR TRIAZINE FUSED BICYCLIC METALLOPROTEASE INHIBITORS ALANTOS-PHARMACEUTICALS, INC. (US) 2006-11-30 WO disclosed
US-4144341-A ANTIPYRETICS, ANALGESICS AND ANTIINFLAMMATORY AGENTS MERCK & CO., INC. (US) 1979-03-13 US disclosed
US-4000286-A ANALGESICS, ANTIINFLAMMATORY AND ANTIPYRETIC AGENTS MERCK & CO., INC. (US) 1976-12-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130331377-A1 DIAMINOPYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF HRH2, GIPR, SSTR4 CDK9 557/4885DYRK1A 227/4885DYRK2 160/4885
US-10640490-B2 Diaminopyrimidine derivatives and processes for the preparation thereof HRH2, GIPR, SSTR4 CDK9 557/4885DYRK1A 227/4885DYRK2 160/4885
US-20180072705-A1 DIAMINOPYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF HRH2, GIPR, SSTR4 CDK9 557/4885DYRK1A 227/4885DYRK2 160/4885
US-20230174488-A1 SARS-COV-2 INHIBITORS HAVING COVALENT MODIFICATIONS FOR TREATING CORONAVIRUS INFECTIONS ACE2, SARS1, ACE CDK9 535/4885DYRK1A 4453/4885DYRK2 3420/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.